{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:08:23Z","timestamp":1791623303597,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pneumonia remains a major cause of childhood illness and death globally, especially in low- and middle-income countries. Despite antibiotic therapy, persistent inflammation and lung injury may delay recovery. This study aimed to evaluate the efficacy of oral pentoxifylline (PTX), combined with standard antibiotic and supportive therapies, for treating hospitalized children with Community-acquired pneumonia (CAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized controlled trial, 106 children with CAP were randomly assigned to receive either oral pentoxifylline plus standard antibiotic and supportive therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200953) or standard therapy alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200953), per institutional guidelines. Treatment response was evaluated using predefined clinical criteria (respiratory rate and oxygen saturation), laboratory parameters (hemoglobin, WBC count, CRP, interleukin-6, LDH, D-dimer, serum albumin, and liver enzymes), and lung ultrasound findings, assessed at baseline and after 10 days of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of enrolled patients was 5.61\u2009\u00b1\u20093.31 years, and 45.3% were female. After 10 days, the PTX group demonstrated significantly lower respiratory rates (29.17\u2009\u00b1\u20094.38 vs. 34.02\u2009\u00b1\u20098.29 breaths\/min;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and higher oxygen saturation (97.28\u2009\u00b1\u20091.32% vs. 96.26\u2009\u00b1\u20091.55%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared with controls. Laboratory improvements in the PTX group included higher hemoglobin and serum albumin and lower WBC count, AST, total bilirubin, CRP, LDH, IL-6, and D-dimer levels (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Lung ultrasound revealed fewer affected lung zones (3.81\u2009\u00b1\u20091.75 vs. 5.71\u2009\u00b1\u20092.14;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), greater resolution of confluent B-lines (88.7% vs. 71.7%), and smaller pleural effusions (0.94\u2009\u00b1\u20090.60\u2009cm vs. 1.65\u2009\u00b1\u20090.90\u2009cm;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjunctive oral pentoxifylline improved clinical status, reduced systemic inflammation, and enhanced radiological resolution in children hospitalized with CAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      At ClinicalTrials.gov (Identifier: NCT06265389). First submitted and met quality control criteria on February 11, 2024; first posted publicly on February 19, 2024.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06265389\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06265389<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Many children with community-acquired pneumonia experience delayed recovery despite effective antibiotic therapy due to persistent inflammation and lung injury.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This is the first randomized controlled trial to evaluate the effectiveness of oral pentoxifylline as an adjunct therapy in pediatric pneumonia.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Adjunctive oral pentoxifylline improved clinical outcomes, reduced systemic inflammation, and accelerated lung healing.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-04997-3","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:27:01Z","timestamp":1777994821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral pentoxifylline as a novel adjunct to standard therapy in pediatric community-acquired pneumonia: a randomized controlled trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-4292","authenticated-orcid":false,"given":"Rehab","family":"Elmeazawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal Zaki","family":"AbdElsamea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"El Sharaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mohammed Farid","family":"EL-Moazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Toema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"4997_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/pch\/8.10.616","volume":"8","author":"HD Davies","year":"2003","unstructured":"Davies, H. D. Community-acquired pneumonia in children. Paediatr. Child Health 8, 616\u2013619 (2003).","journal-title":"Paediatr. Child Health"},{"key":"4997_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s13312-021-2369-1","volume":"58","author":"JP Goyal","year":"2021","unstructured":"Goyal, J. P. et al. Acute Respiratory Infection Treatment Unit Study Group. Risk factors for the development of pneumonia and severe pneumonia in children. Indian Pediatr. 58, 1036\u20131039 (2021).","journal-title":"Indian Pediatr."},{"key":"4997_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.medin.2013.01.004","volume":"38","author":"S Trefler","year":"2014","unstructured":"Trefler, S. et al. Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot study. Med. Intensiv. 38, 73\u201382 (2014).","journal-title":"Med. Intensiv."},{"key":"4997_CR4","doi-asserted-by":"publisher","first-page":"176.e7","DOI":"10.1016\/j.jcrc.2009.05.002","volume":"25","author":"YL Lee","year":"2010","unstructured":"Lee, Y. L. et al. Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. J. Crit. Care 25, 176.e7\u201313 (2010).","journal-title":"J. Crit. Care"},{"key":"4997_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1128\/AAC.00658-07","volume":"52","author":"E Calbo","year":"2008","unstructured":"Calbo, E., Alsina, M., Rodr\u00edguez-Carballeira, M., Lite, J. & Garau, J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob. Agents Chemother. 52, 2395\u20132402 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4997_CR6","doi-asserted-by":"publisher","first-page":"173561","DOI":"10.1016\/j.ejphar.2020.173561","volume":"887","author":"F Monji","year":"2020","unstructured":"Monji, F., Al-Mahmood Siddiquee, A. & Hashemian, F. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur. J. Pharm. 887, 173561 (2020).","journal-title":"Eur. J. Pharm."},{"key":"4997_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/j.1552-4604.1985.tb02796.x","volume":"25","author":"HR Dettelbach","year":"1985","unstructured":"Dettelbach, H. R. & Aviado, D. M. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J. Clin. Pharm. 25, 8\u201326 (1985).","journal-title":"J. Clin. Pharm."},{"key":"4997_CR8","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3390\/jcm10225305","volume":"10","author":"W Feret","year":"2021","unstructured":"Feret, W. et al. Pentoxifylline as a potential adjuvant therapy for COVID-19: Impeding The Burden Of The Cytokine Storm. J. Clin. Med. 10, 5305 (2021).","journal-title":"J. Clin. Med"},{"key":"4997_CR9","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2011-200598","volume":"66","author":"M Harris","year":"2011","unstructured":"Harris, M. et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 66, ii1\u2013ii23 (2011).","journal-title":"Thorax"},{"key":"4997_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(20)31550-6","volume":"396","author":"FM de Benedictis","year":"2020","unstructured":"de Benedictis, F. M. et al. Complicated pneumonia in children. Lancet 396, 786\u201379 (2020).","journal-title":"Lancet"},{"key":"4997_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0011-393X(03)00018-3","volume":"64","author":"BM Best","year":"2003","unstructured":"Best, B. M. et al. Pediatric Pharmacology Research Unit Network. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in Kawasaki disease. Curr. Ther. Res. Clin. Exp. 64, 96\u2013115 (2003).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"4997_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00134-012-2513-4","volume":"38","author":"G Volpicelli","year":"2012","unstructured":"Volpicelli, G. et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 38, 577\u2013591 (2012).","journal-title":"Intensive Care Med."},{"key":"4997_CR13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00247-017-3910-1","volume":"47","author":"JAM Stadler","year":"2017","unstructured":"Stadler, J. A. M., Andronikou, S. & Zar, H. J. Lung ultrasound for the diagnosis of community-acquired pneumonia in children. Pediatr. Radio. 47, 1412\u20131419 (2017).","journal-title":"Pediatr. Radio."},{"key":"4997_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-4-1","volume":"4","author":"DA Lichtenstein","year":"2014","unstructured":"Lichtenstein, D. A. Lung ultrasound in the critically ill. Ann. Intensive Care 4, 1 (2014).","journal-title":"Ann. Intensive Care"},{"key":"4997_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1378\/chest.08-2281","volume":"135","author":"D Lichtenstein","year":"2009","unstructured":"Lichtenstein, D., Mezi\u00e8re, G. & Seitz, J. The dynamic air bronchogram. A lung ultrasound sign of alveolar consolidation ruling out atelectasis. Chest 135, 1421\u20131425 (2009).","journal-title":"Chest"},{"key":"4997_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ajem.2008.03.009","volume":"27","author":"S Parlamento","year":"2009","unstructured":"Parlamento, S., Copetti, R. & Di Bartolomeo, S. Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED. Am. J. Emerg. Med. 27, 379\u2013384 (2009).","journal-title":"Am. J. Emerg. Med"},{"key":"4997_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130082","volume":"10","author":"SH Lai","year":"2015","unstructured":"Lai, S. H., Wong, K. S. & Liao, S. L. Value of Lung Ultrasonography In The Diagnosis And Outcome Prediction Of Pediatric Community-acquired Pneumonia With Necrotizing Change. PLoS One 10, e0130082 (2015).","journal-title":"PLoS One"},{"key":"4997_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40477-021-00577-9","volume":"25","author":"R Montero-Y\u00e9boles","year":"2022","unstructured":"Montero-Y\u00e9boles, R. et al. A pleural ultrasound image of a collapsed lung surrounded by pleural fluid (\u201cjellyfish sign\u201d) may correspond to an intrapericardial mass. J. Ultrasound 25, 387\u2013390 (2022).","journal-title":"J. Ultrasound"},{"key":"4997_CR19","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.5114\/pjr.2023.128866","volume":"88","author":"P \u0141y\u017aniak","year":"2023","unstructured":"\u0141y\u017aniak, P., \u015awi\u0119to\u0144, D., Serafin, Z. & Szurowska, E. Lung ultrasound in a nutshell. Lines, signs, some applications, and misconceptions from a radiologist\u2019s point of view. Pol. J. Radio. 88, e294\u2013e310 (2023).","journal-title":"Pol. J. Radio."},{"key":"4997_CR20","first-page":"1015","volume":"9","author":"A Ammirabile","year":"2021","unstructured":"Ammirabile, A., Buonsenso, D. & Di Mauro, A. Lung Ultrasound in Pediatrics and Neonatology: An Update. Healthc. (Basel) 9, 1015 (2021).","journal-title":"Healthc. (Basel)"},{"key":"4997_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/jhm.2370","volume":"10","author":"RB Wolf","year":"2015","unstructured":"Wolf, R. B. et al. Time to clinical stability among children hospitalized with pneumonia. J. Hosp. Med 10, 380\u2013383 (2015).","journal-title":"J. Hosp. Med"},{"key":"4997_CR22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063480","volume":"153","author":"MR Field","year":"2024","unstructured":"Field, M. R. et al. Time to Clinical Stability In Children With Community-acquired Pneumonia. Pediatrics 153, e2023063480 (2024).","journal-title":"Pediatrics"},{"key":"4997_CR23","doi-asserted-by":"publisher","first-page":"108227","DOI":"10.1016\/j.intimp.2021.108227","volume":"101","author":"H Azizi","year":"2021","unstructured":"Azizi, H. et al. Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial. Int Immunopharmacol. 101, 108227 (2021).","journal-title":"Int Immunopharmacol."},{"key":"4997_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","volume":"372","author":"S Jain","year":"2015","unstructured":"Jain, S. et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 372, 835\u2013845 (2015).","journal-title":"N. Engl. J. Med"},{"key":"4997_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13052-019-0697-8","volume":"45","author":"J Tian","year":"2019","unstructured":"Tian, J., Shen, P., Pan, K. & Zhou, Q. Efficacy of pentoxifylline treatment for neonatal sepsis: a meta-analysis of randomized controlled studies. Ital. J. Pediatr. 45, 108 (2019).","journal-title":"Ital. J. Pediatr."},{"key":"4997_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/crj.12646","volume":"12","author":"L Wang","year":"2018","unstructured":"Wang, L. & Song, Y. Efficacy of zinc given as an adjunct to the treatment of severe pneumonia: A meta-analysis of randomized, double-blind and placebo-controlled trials. Clin. Respir. J. 12, 857\u2013864 (2018).","journal-title":"Clin. Respir. J."},{"key":"4997_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ccm.2018.07.008","volume":"39","author":"A Ceccato","year":"2018","unstructured":"Ceccato, A., Ferrer, M., Barbeta, E. & Torres, A. Adjunctive Therapies For Community-acquired Pneumonia. Clin. Chest Med. 39, 753\u2013764 (2018).","journal-title":"Clin. Chest Med."},{"key":"4997_CR28","doi-asserted-by":"publisher","first-page":"107209","DOI":"10.1016\/j.intimp.2020.107209","volume":"90","author":"V Maldonado","year":"2021","unstructured":"Maldonado, V. et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. Int. Immunopharmacol. 90, 107209 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"4997_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/ph16040631","volume":"16","author":"RM Sarhan","year":"2023","unstructured":"Sarhan, R. M. et al. PentoxifyllinE effects on hospitalized COVID-19 patients with Cytokine Storm Syndrome: a randomized clinical trial. Pharmaceuticals 16, 631 (2023).","journal-title":"Pharmaceuticals"},{"key":"4997_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","volume":"17","author":"BR Don","year":"2004","unstructured":"Don, B. R. & Kaysen, G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 17, 432\u2013437 (2004).","journal-title":"Semin Dial."},{"key":"4997_CR31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1097\/01.ASN.0000131523.17045.56","volume":"15","author":"A Cooper","year":"2004","unstructured":"Cooper, A., Mikhail, A., Lethbridge, M. W., Kemeny, D. M. & Macdougall, I. C. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J. Am. Soc. Nephrol. 15, 1877\u20131882 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4997_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15171\/jrip.2017.11","volume":"6","author":"H Shahbazian","year":"2016","unstructured":"Shahbazian, H. et al. Administration of pentoxifylline to improve anemia of hemodialysis patients. J. Ren. Inj. Prev. 6, 61\u201364 (2016).","journal-title":"J. Ren. Inj. Prev."},{"key":"4997_CR33","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"4997_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","volume":"126","author":"MJ Delano","year":"2016","unstructured":"Delano, M. J. & Ward, P. A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Invest. 126, 23\u201331 (2016).","journal-title":"J. Clin. Invest."},{"key":"4997_CR35","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ndt\/gfr579","volume":"27","author":"L Gonz\u00e1lez-Espinoza","year":"2012","unstructured":"Gonz\u00e1lez-Espinoza, L. et al. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol. Dial. Transpl. 27, 2023\u20132028 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"4997_CR36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.csbj.2021.02.009","volume":"19","author":"AP Chavarr\u00eda","year":"2021","unstructured":"Chavarr\u00eda, A. P. et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput. Struct. Biotechnol. J. 19, 1379\u20131390 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"4997_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10787-022-00993-1","volume":"30","author":"G Mostafa-Hedeab","year":"2022","unstructured":"Mostafa-Hedeab, G. et al. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology 30, 799\u2013809 (2022).","journal-title":"Inflammopharmacology"},{"key":"4997_CR38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/QAD.0b013e3283396024","volume":"24","author":"SK Gupta","year":"2010","unstructured":"Gupta, S. K. et al. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 24, 1377\u20131380 (2010).","journal-title":"AIDS"},{"key":"4997_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1665-2681(19)31363-8","volume":"12","author":"M\u00c1 Jim\u00e9nez-Lu\u00e9vano","year":"2013","unstructured":"Jim\u00e9nez-Lu\u00e9vano, M. \u00c1, Lerma-D\u00edaz, J. M., Hern\u00e1ndez-Flores, G., Jim\u00e9nez-Partida, M. \u00c1 & Bravo-Cuellar, A. Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial. Ann. Hepatol. 12, 248\u2013255 (2013).","journal-title":"Ann. Hepatol."},{"key":"4997_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2710.2009.01077.x","volume":"35","author":"M Adel","year":"2010","unstructured":"Adel, M., Awad, H. A., Abdel-Naim, A. B. & Al-Azizi, M. M. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J. Clin. Pharm. Ther. 35, 257\u2013265 (2010).","journal-title":"J. Clin. Pharm. Ther."},{"key":"4997_CR41","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1097\/INF.0b013e318255dc5b","volume":"31","author":"S Esposito","year":"2012","unstructured":"Esposito, S. et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr. Infect. Dis. J. 31, e78\u2013e85 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"4997_CR42","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","volume":"53","author":"JS Bradley","year":"2011","unstructured":"Bradley, J. S. et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 53, e25\u2013e76 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"4997_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1378\/chest.07-2800","volume":"134","author":"DA Lichtenstein","year":"2008","unstructured":"Lichtenstein, D. A. & Mezi\u00e8re, G. A. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. Chest 134, 117\u2013125 (2008).","journal-title":"Chest"},{"key":"4997_CR44","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/jum.15284","volume":"39","author":"G Soldati","year":"2020","unstructured":"Soldati, G. et al. Is there a role for lung ultrasound during the COVID-19 pandemic? J. Ultrasound Med. 39, 1459\u20131462 (2020).","journal-title":"J. Ultrasound Med."},{"key":"4997_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/2036-7902-4-16","volume":"4","author":"JW Tsung","year":"2012","unstructured":"Tsung, J. W., Kessler, D. O. & Shah, V. P. Prospective application of clinician-performed lung ultrasonography during the 2009 H1N1 influenza A pandemic: distinguishing viral from bacterial pneumonia. Crit. Ultrasound J. 4, 16 (2012).","journal-title":"Crit. Ultrasound J."},{"key":"4997_CR46","doi-asserted-by":"publisher","first-page":"828437","DOI":"10.3389\/fped.2022.828437","volume":"10","author":"J Qiu","year":"2022","unstructured":"Qiu, J., Ge, J. & Cao, L. D-dimer: The risk factor of children\u2019s severe mycoplasma pneumoniae pneumonia. Front. Pediatr. 10, 828437 (2022).","journal-title":"Front. Pediatr."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04997-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:03:02Z","timestamp":1778061782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04997-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":46,"alternative-id":["4997"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-04997-3","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and its later amendments. The research ethics committee of the Faculty of Medicine, Tanta University, has approved this research under the number 36264PR502\/1\/24.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patients\u2019 guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}]}}